Morepen Laboratories zooms on launching Empamore
Morepen Laboratories is currently trading at Rs. 48.01, up by 5.21 points or 12.17% from its previous closing of Rs. 42.80 on the BSE.
The scrip opened at Rs. 43.71 and has touched a high and low of Rs. 48.20 and Rs. 43.71 respectively. So far 791028 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 100.80 on 10-Sep-2024 and a 52 week low of Rs. 40.23 on 20-Mar-2024.
Last one week high and low of the scrip stood at Rs. 48.20 and Rs. 42.55 respectively. The current market cap of the company is Rs. 2603.33 crore.
The promoters holding in the company stood at 35.65%, while Institutions and Non-Institutions held 3.87% and 60.47% respectively.
Morepen Laboratories has launched Empamore, a game-changing treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD). With India being the diabetes capital of the world and over 101 million people suffering from the disease, Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health.
Morepen manufactures Empagliflozin (API) in its USFDA-approved facilities and already has European DMF. The launch of Empamore reflects Morepen’s 40 years of pharmaceutical excellence, providing a cost-effective alternative to leading brands while ensuring affordability without compromising quality. The product range includes Empagliflozin (Empamore 10mg/25mg) and Empagliflozin 12.5mg with Metformin 500/1000mg (Empamore M 500/1000mg).
Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs, Home Diagnostics, Formulations and OTC products.
